Related references
Note: Only part of the references are listed.Ischemic Stroke and Pulmonary Arteriovenous Malformations
Karan K. Topiwala et al.
NEUROLOGY (2022)
Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management
Fiammetta Vanoli et al.
NEUROTHERAPEUTICS (2022)
International Consensus Guidance for Management of Myasthenia Gravis 2020 Update
Pushpa Narayanaswami et al.
NEUROLOGY (2021)
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial
Gil I. Wolfe et al.
LANCET NEUROLOGY (2019)
Myasthenia gravis
Nils Erik Gilhus et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Serological and experimental studies in different forms of myasthenia gravis
Angela Vincent et al.
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (2018)
Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis
Karen Hewett et al.
NEUROLOGY (2018)
Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action
Douglas Sheridan et al.
PLOS ONE (2018)
When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies
Renato Mantegazza et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2018)
Thymus involvement in early-onset myasthenia gravis
Melanie A. Cron et al.
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (2018)
IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients
Inga Koneczny et al.
JOURNAL OF AUTOIMMUNITY (2017)
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
James F. Howard et al.
LANCET NEUROLOGY (2017)
Myasthenia Gravis
Nils E. Gilhus
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Randomized Trial of Thymectomy in Myasthenia Gravis
G. I. Wolfe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis Patients (vol 9, e108327, 2014)
G. Kordas et al.
PLOS ONE (2015)
EFNS/ENS Guidelines for the treatment of ocular myasthenia
E. Kerty et al.
EUROPEAN JOURNAL OF NEUROLOGY (2014)
The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes
Alexander Marx et al.
AUTOIMMUNITY REVIEWS (2013)
Complement associated pathogenic mechanisms in myasthenia gravis
Erdem Tuzun et al.
AUTOIMMUNITY REVIEWS (2013)
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome
C. M. Legendre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4
Maartje G. Huijbers et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Autoantibodies to Low-Density Lipoprotein Receptor-Related Protein 4 in Myasthenia Gravis
Osamu Higuchi et al.
ANNALS OF NEUROLOGY (2011)
THE THYMUS IN MYASTHENIA GRAVIS: SITE OF INNATE AUTOIMMUNITY?
Paola Cavalcante et al.
MUSCLE & NERVE (2011)
Current and emerging therapies for the treatment of myasthenia gravis
Renato Mantegazza et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2011)
The ageing and myasthenic thymus: A morphometric study validating a standard procedure in the histological workup of thymic specimens
Philipp Stroebel et al.
JOURNAL OF NEUROIMMUNOLOGY (2008)
FDA Report: Eculizumab (Soliris (R)) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
Andrew Dmytrijuk et al.
ONCOLOGIST (2008)
Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG
MI Leite et al.
ANNALS OF NEUROLOGY (2005)
The immunologic role of thymectomy in the treatment of myasthenia gravis: Implication of thymus-associated B-lymphocyte subset in reduction of the anti-acetylcholine receptor antibody titer
M Okumura et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2003)
Share Paper
